New imaging agent shows promise for kidney cancer detection
NCT ID NCT06840548
First seen Jan 20, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested a new radioactive imaging agent called 68Ga-OncoCAIX in 20 people with clear cell renal cell carcinoma, a type of kidney cancer. The goal was to see if it is safe and how it spreads in the body to help detect tumors. Participants received a single dose, and researchers measured radiation exposure and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASST Papa Giovanni XXIII
Bergamo, BG, 24127, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
IRCCS Ospedale San Raffaele
Milan, Milano, 20132, Italy
Conditions
Explore the condition pages connected to this study.